Rising Demand For Personalized Medicine Promoting the Global Metagenomic Sequencing Market

Global metagenomic sequencing market is anticipated to grow at a considerable CAGR of 7.6% during the forecast period (2024-2031). A major factor supporting the growth of the market is the increasing demand for personalised medicine and precision healthcare. Metagenomic sequencing enables researchers and clinicians to analyse the genetic material of complex microbial communities within the human body, environmental samples, or other ecosystems that provide valuable insights into the diversity and functions of microorganisms, facilitating the development of targeted therapies, diagnostics, and interventions tailored to individual patients or specific environmental conditions.

Browse the full report description of “Metagenomic Sequencing Market Size, Share & Trends Analysis Report by Type (Drug Discovery, Clinical Diagnostic, Soil Microbiome, Industrial Applications, Ecological and Environmental and Veterinary), by Product & Service (Reagents and Consumables, Instruments, Sequencing Services and Analysis and Data Interpretation Solutions), by Technology (16s Rna Sequencing, Shotgun Metagenomic Sequencing, Whole-Genome Sequencing and De Novo Assembly and Metatranscrigptomics) and by Workflow (Sample Preparation, Sequencing and Data Processing and Analysis) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/metagenomic-sequencing-market

Looking towards the rising sequencing demand, in September 2021, Thermo Fisher Scientific, Inc., based in the US, collaborated with AstraZeneca, headquartered in the UK, to jointly develop a next-generation sequencing (NGS)-based companion diagnostic. The partnership's focus was on commercializing NGS-based diagnostics within the Russian market.

Additionally, in February 2021, PacBio, a company specializing in genomic sequencing technology, announced that Children's Mercy Kansas City expanded its investment in highly accurate HiFi sequencing with the addition of four new Sequel IIe Systems, complementing its existing two Sequel IIe Systems.

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered- 

o By Type

o By Product & Service

o By Technology

o By Workflow

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- includesF. Hoffmann-La Roche Ltd., AstraZeneca, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., and Eurofins Scientific among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Metagenomic Sequencing Market Report Segment

By Type

• Drug Discovery
• Clinical Diagnostic
• Soil Microbiome
• Industrial Applications
• Ecological and Environmental
• Veterinary

By Product & Service

• Reagents and Consumables
• Instruments
• Sequencing Services
• Analysis and Data Interpretation Solutions

By Technology

• 16s Rna Sequencing
• Shotgun Metagenomic Sequencing
• Whole-Genome Sequencing and De Novo Assembly
• Metatranscriptomics

By Workflow

• Sample Preparation
• Sequencing
• Data Processing and Analysis

Global Metagenomic Sequencing Market Report Segment by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/metagenomic-sequencing-market